Top Industry Leaders in the Eye Melanoma Market
iOnctura Receives IND Approval for Uveal Melanoma Treatment: Swiss company iOnctura received FDA Investigational New Drug (IND) approval for roginolisib, a PI3K/AKT/mTOR inhibitor for uveal melanoma. This paves the way for Phase I clinical trials.
Meru Biosciences Licenses MCLA-145 for Eye Melanoma: Meru Biosciences entered a licensing agreement with OncoMed Pharmaceuticals for MCLA-145, a SHP2 inhibitor with potential for treating uveal melanoma and other cancers.
EyePoint Pharmaceuticals Initiates Phase 2 Trial for Y-mAbs Therapitics: EyePoint Pharmaceuticals began a Phase 2 trial evaluating the safety and efficacy of Y-mAbs Therapitics' anti-PD-1 antibody, YH001, in combination with standard therapy for uveal melanoma.
Roche Presents Positive Data on Tecentriq for Eye Melanoma: Roche presented encouraging data from a Phase 2 study demonstrating the potential of Tecentriq (atezolizumab), an anti-PD-L1 antibody, in combination with Zelboraf (vemurafenib) for treating metastatic uveal melanoma.
List of Eye Melanoma Key Companies in the Market
- Castle Biosciences Inc. (U.S.)
- GENERAL ELECTRIC (U.S.)
- Koninklijke Philips N.V. (The Netherlands)
- TOSHIBA CORPORATION (Japan)
- Siemens AG (Germany)
- Analogic Corporation (U.S.)
- Optovue
- Incorporated (U.S.)
- NOVADAQ Technologies Inc. (Canada)
- Agfa-Gevaert Group (Belgium)
- and ZEISS (Germany)